Dr. Reddy’s Laboratories-Q3 FY26 Earnings Call Note-Revenue edged up 4.4% year-over-year to ₹8,727 crore

Dr. Reddy’s Laboratories (DRREDDY) Q3 FY26 Earnings: Base Business Shines, But Lenalidomide Fade Hits Profits

Dr. Reddy’s Laboratories delivered a mixed set of numbers in its fiscal third quarter ending December 2025. Revenue edged up 4.4% year-over-year to ₹8,727 crore (about $971 million), helped by solid gains in India, emerging markets, and favorable currency moves. Yet profit after tax dropped 14% to ₹1,210 crore ($135 million), with diluted EPS at ₹14.52. The headline profit miss came mainly from lower high-margin sales of Lenalidomide in the US, plus ongoing price pressure in generics and a one-time hit from new Indian labor code changes.

Adjusted for that one-off provision, EBITDA margin held up at 24.8% – close to management’s 25% target level. The underlying base business (excluding Lenalidomide) grew in double digits, which management highlighted as proof that core operations remain healthy. Investors seemed to focus more on that resilience than the profit dip: the stock jumped around 5-6% the next trading day, showing relief that the quarter beat some expectations on revenue quality and India momentum.

Overall, the print reflects a company in transition. Legacy US profit drivers are fading, but branded franchises in India and emerging markets, plus early biosimilar and Semaglutide progress, are picking up the slack. Near-term margins face pressure, but longer-term pipeline visibility gives reason for cautious optimism.

Dr. Reddy’s Laboratories-Key Financial Highlights

• Consolidated revenue: ₹8,727 crore ($971 million), +4.4% YoY, –0.9% QoQ
• Gross profit margin: 53.6% (-505 bps YoY), adjusted to 54.1% ex one-off
• Reported EBITDA: ₹2,049 crore ($228 million), –11% YoY
• Adjusted EBITDA margin: 24.8% (reported 23.5%, hit by labor provision)
• Profit before tax: ₹1,543 crore, 17.7% of revenue (19% adjusted)
• Profit after tax: ₹1,210 crore ($135 million), –14% YoY, –16% QoQ
• Diluted EPS: ₹14.52
• Net cash surplus: ₹3,069 crore ($342 million)
• Free cash flow: ₹374 crore ($42 million)
• Capex outflow: ₹669 crore ($75 million)

The numbers show topline holding up despite Lenalidomide weakness, but bottom-line pressure from mix shift, pricing, and the one-time cost.

Vedanta Ltd -Q3 FY26 Earnings Call-highest-ever quarterly revenue of ₹45,899 crore

Segment Performance Breakdown

North America Generics ($338 million revenue) fell 16% YoY and 9% QoQ. Lower Lenalidomide sales and price erosion in base products drove most of the drop. Still, six new launches kept some momentum.

Europe Generics ($140 million) grew 4% YoY and sequentially. The acquired nicotine replacement therapy (NRT) business helped, plus ten new generic launches offset pricing pressure.

Emerging Markets (₹1,896 crore) jumped 32% YoY and 15% QoQ. New launches (30 products) and forex gains fueled the rise. Russia grew 21% YoY in constant currency despite tough macro conditions.

India (₹1,603 crore) rose 19% YoY and 2% QoQ. Organic growth topped 17% even after stripping out the Stugeron acquisition. Management pointed to innovation brands, new launches, price hikes, volume gains, and outperformance vs. the Indian market (MQT growth 12.3% vs. IPM 11.8%; MAT 9.7% vs. 8.9%). Rank improved to 9-10 in recent months.

PSA (Pharma Services & API) ($92 million) declined 5% YoY and 15% QoQ due to adverse mix.

The clear message: branded and emerging markets are carrying growth while US generics normalize post-Lenalidomide.

Management Commentary and Strategic Focus

CEO Erez Israeli struck a confident tone on base-business strength.

“Our underlying base business delivered overall a double-digit growth this quarter. The company EBITDA margin was about 25%. This is adjusted for one-time provision related to the New Labor Codes in India.”

He stressed execution on four priorities: base growth, pipeline advancement (Semaglutide, Abatacept, others), operational efficiencies, and selective deals.

Key pipeline updates included:

• Semaglutide injection approved in India; filings started in emerging markets; response filed to Health Canada non-compliance notice
• Abatacept IV BLA filed in US; Ustekinumab biosimilar approved in EU/UK, launched in Germany
• Ustekinumab US CRL due to partner Alvotech facility issues
• New oncology collaboration with Immutep (upfront $20 million, milestones up to $350 million)
• Hepatitis E vaccine launched in India
• NRT integration 85% complete by value; full wrap-up expected by fiscal year-end

CFO MV Narasimham explained margin pressure clearly: lower Lenalidomide, US/Europe pricing, mix in PSA, and the labor provision. Adjusted figures showed underlying stability.

The tone felt steady – no panic over US softness, strong belief in India/emerging scale-up, and realism about pipeline timelines.

Guidance and Forward Outlook

No formal full-year guidance was given (typical for the company). Management reiterated focus on double-digit base growth, pipeline execution, and efficiencies.

They expect negligible Lenalidomide from Q4 onward, so comparisons get tougher. Semaglutide ramp-up in India and emerging markets, plus Abatacept progress, form the big levers for FY27 and beyond.

Analysts noted the quarter beat on revenue quality (strong India/Russia), but flagged caution on US visibility and Semaglutide/Canada timelines.

Positives to Watch

• India momentum – sustained high-teens organic growth signals strong branded franchise and market outperformance
• Emerging markets strength – 32% YoY growth shows diversification paying off
• Pipeline milestones – Semaglutide India launch underway; Abatacept filings on track
• Balance sheet – net cash $342 million, low debt risk
• NRT integration – progressing well, adding stable consumer revenue
• Sustainability push – net-zero target by FY42 positions the company as a leader among Indian pharma peers

Risks and Concerns

• Lenalidomide cliff – high-margin US sales now minimal, creating tough comps
• US pricing pressure – continued erosion in base generics caps recovery speed
• Regulatory hurdles – Canada Semaglutide delay; US CRL on Ustekinumab; ongoing Form 483 resolutions
• Margin headwinds – mix shift to lower-margin markets, limited cost levers post-labor provision
• Competition intensity – biosimilars and Semaglutide face crowded fields in key markets
• Forex and macro – emerging market reliance brings currency and geopolitical risk (Russia noted)

Capital Allocation

Dr. Reddy’s maintains a conservative stance. Net cash surplus stayed healthy at $342 million. Capex was $75 million in the quarter, focused on biologics and API facilities. No major buyback or dividend update in the call, but free cash flow generation ($42 million) supports flexibility for pipeline investment or selective M&A.

The Immutep deal (upfront $20 million + milestones) shows willingness for bolt-on innovation in emerging markets.

Broader Challenges

• US generics normalization after complex products like Lenalidomide
• Rising competition in GLP-1 (Semaglutide) space globally
• Regulatory scrutiny on manufacturing (recent Form 483s and CRLs)
• Indian labor code changes adding one-time costs
• Currency volatility in emerging markets

 

On India business growth and organic contribution Question: How much of the 19% India growth was organic vs. Stugeron acquisition? Would ex-acquisition growth still be north of 15%? Answer: Management confirmed organic growth was more than 17% without acquisitions. Our take: This was reassuring – it shows the domestic engine runs strong on innovation brands, volume, and pricing, not just bolt-on deals. Sustainability looks solid.

On drivers of India growth and sustainability Question: What is driving the strong India performance, and is it sustainable? Answer: CEO Erez Israeli highlighted innovative products performing well in the market, contributing 10-15% of sales overall. Growth feels durable as new brands gain traction. Our take: Management sounded upbeat and specific on the innovation franchise – a key differentiator vs. pure generics peers in India.

On Semaglutide approval timeline in Canada Question: What are expectations for Semaglutide approval in Canada, and what is the timeline? Answer: Company responded to the non-compliance notice by mid-November 2025. Health Canada has a goal date around May 2026 (six months from response), but approval could come earlier. Preparing for potential launch in Q4 FY26 or Q1 FY27. Our take: No major red flags – response was timely, and the goal date gives a clear window. Investors wanted this clarity after the October notice.

On Semaglutide pricing and competition in emerging markets Question: What is the pricing and competition landscape for Semaglutide in key markets? Answer: Pricing still expected in the $20–$70 range per month across markets, with most on the lower end. Competition will likely compress prices over time as more players enter. Our take: Realistic view – management isn’t banking on premium pricing long-term. Emerging markets focus means volume over margin in many places.

On Abatacept US timeline and Europe outlook Question: What are the US and Europe timelines for Abatacept? Answer: IV approval expected toward end of calendar 2026. Subcutaneous approval aligned with patent expiry in Jan/Feb 2028. Europe submission planned for July 2026, potential launch July 2027 (12-month review). European market estimated at ~$2 billion. Our take: Timelines feel measured and achievable. Europe market size gives scale potential post-launch.

On Rituximab US delay impact Question: What is the impact of the delayed Rituximab launch in the US? Answer: Ongoing work to resolve post-PAI observations at Bachupally facility. No specific new launch date given, but active progress noted. Our take: Slight caution here – biosimilar delays are common, but repeated Form 483/CRL themes keep regulatory risk in focus for investors.

On NRT integration and contribution Question: How is NRT integration progressing, and what contribution is it making? Answer: 85% of business by value under operational control. Next phase covers Asia Pacific, Middle East, Latin America. Full integration expected by fiscal year-end. Performing well and now part of base. Our take: Steady update – consumer healthcare addition is helping stabilize Europe and add non-cyclical revenue.

Key Takeaway

Dr. Reddy’s Q3 FY26 showed a company successfully pivoting. The Lenalidomide era is winding down, pressuring profits short-term, but double-digit base growth, strong India/emerging performance, and pipeline steps forward point to a healthier core story. Investors liked the quality of growth enough to bid shares higher post-results.

Near-term focus stays on Semaglutide rollout speed and biosimilar resolutions. If management delivers on those, the transition could prove smoother than feared. For now, it’s a resilient quarter in a normalizing environment – not fireworks, but solid progress where it counts.